Redosing With CP-870, 893 in Patients With Clinical Benefit After a Single Infusion From A Phase I, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors
Clinical trial NCT02157831 · COMPLETED
Trial details
- NCT number
- NCT02157831
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Status
- COMPLETED
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2005-07-01
- Primary completion
- 2008-02-01
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.